Thomas Rice - Chemed Corp Independent Director
| CHE Stock | USD 447.74 5.66 1.25% |
Director
Mr. Thomas P. Rice serves as an Independent Director of the Company. Mr. Rices experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporationrationration, Fort Lauderdale, Florida, from February 2004 to November 2006, when Andrx was sold to Watson Pharmaceuticals. Following the sale, Mr. Rice returned as General Manager and Majority Partner of Columbia Investments LLC, Baltimore, Maryland, which invests in local emerging businesses in Baltimore and which Mr. Rice cofounded in January 1996. He was also a Director of Par Pharmaceuticals, Woodcliff Lake, NJ until November 2012. From January 1999 to March 2003, he was President and Chief Executive Officer of Chesapeake Biological Laboratories, Inc., Solomons, Maryland . Before cofounding Columbia Investments LLC, Mr. Rice served as Executive Vice President and Chief Operating Officer of Circa Pharmaceuticals, Inc., Copiague, New York, from June 1993 to January 1996 since 2009.
| Age | 70 |
| Tenure | 17 years |
| Address | 255 East Fifth Street, Cincinnati, OH, United States, 45202-4726 |
| Phone | 513 762 6690 |
| Web | https://www.chemed.com |
Chemed Corp Management Efficiency
The company has Return on Asset of 0.1297 % which means that on every $100 spent on assets, it made $0.1297 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2411 %, implying that it generated $0.2411 on every 100 dollars invested. Chemed Corp's management efficiency ratios could be used to measure how well Chemed Corp manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Assets is expected to grow to 0.17, whereas Return On Tangible Assets are forecasted to decline to 0.15. At present, Chemed Corp's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 176.4 M, whereas Other Assets are projected to grow to (107.9 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stuart Randle | Teleflex Incorporated | 66 | |
| Paul Diaz | DaVita HealthCare Partners | 58 | |
| Charles Berg | DaVita HealthCare Partners | 63 | |
| Steven Paladino | Henry Schein | 67 | |
| Andrew Krakauer | Teleflex Incorporated | 66 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Pascal Desroches | DaVita HealthCare Partners | 55 | |
| Mark Mlotek | Henry Schein | 70 | |
| Candace Duncan | Teleflex Incorporated | 67 | |
| Maritza Montiel | AptarGroup | 69 | |
| John Nehra | DaVita HealthCare Partners | 71 | |
| Joanne Smith | AptarGroup | 59 | |
| Ralf Wunderlich | AptarGroup | 55 | |
| Phyllis Yale | DaVita HealthCare Partners | 62 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| George Babich | Teleflex Incorporated | 69 | |
| Jesse Wu | AptarGroup | 62 | |
| Gretchen Haggerty | Teleflex Incorporated | 65 | |
| John Heinmiller | Teleflex Incorporated | 66 | |
| Barbara Desoer | DaVita HealthCare Partners | 67 | |
| Andreas Kramvis | AptarGroup | 68 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 |
Chemed Corp Leadership Team
Elected by the shareholders, the Chemed Corp's board of directors comprises two types of representatives: Chemed Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemed. The board's role is to monitor Chemed Corp's management team and ensure that shareholders' interests are well served. Chemed Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemed Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Naomi Dallob, Vice President and the Secretary and Chief Legal Officer | ||
| Joel Gemunder, Independent Director | ||
| Holley Schmidt, Vice Controller | ||
| Sherri Warner, Director Relations | ||
| Nicholas Westfall, Executive Vice President | ||
| Christopher Heaney, Independent Director | ||
| Joel Wherley, President Healthcare | ||
| Walter Krebs, Independent Director | ||
| Nathan McNamara, VP Officer | ||
| David Williams, Chief Financial Officer, Executive Vice President | ||
| Andrea Lindell, Independent Director | ||
| George Walsh, Independent Chairman of the Board | ||
| Thomas Rice, Independent Director | ||
| Patrick Grace, Independent Director | ||
| Frank Wood, Independent Director | ||
| Thomas Hutton, VP Director | ||
| Kevin McNamara, President, Chief Executive Officer, Director | ||
| Spencer Lee, Executive Vice President | ||
| Ron DeLyons, Independent Director | ||
| Thomas JD, VP Director | ||
| Donald Saunders, Independent Director | ||
| Michael Witzeman, Principal Accounting Officer, Controller | ||
| Lisa Reinhard, Chief VP | ||
| Brian Judkins, Vice President Chief Legal Officer, Secretary | ||
| Brian JD, Secretary VP |
Chemed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemed Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 6.33 B | ||||
| Shares Outstanding | 14.11 M | ||||
| Shares Owned By Insiders | 2.01 % | ||||
| Shares Owned By Institutions | 97.99 % | ||||
| Number Of Shares Shorted | 619.17 K | ||||
| Price To Earning | 25.42 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chemed Corp is a strong investment it is important to analyze Chemed Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Chemed Corp's future performance. For an informed investment choice regarding Chemed Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemed Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Chemed Stock refer to our How to Trade Chemed Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Will Health Care Providers & Services sector continue expanding? Could Chemed diversify its offerings? Factors like these will boost the valuation of Chemed Corp. Projected growth potential of Chemed fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Chemed Corp data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.11) | Dividend Share 2.1 | Earnings Share 18.89 | Revenue Per Share | Quarterly Revenue Growth 0.031 |
The market value of Chemed Corp is measured differently than its book value, which is the value of Chemed that is recorded on the company's balance sheet. Investors also form their own opinion of Chemed Corp's value that differs from its market value or its book value, called intrinsic value, which is Chemed Corp's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Chemed Corp's market value can be influenced by many factors that don't directly affect Chemed Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Chemed Corp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Chemed Corp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Chemed Corp's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.